Essilor Prescription Safety Eyewear Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Essilor Prescription Safety Eyewear's estimated annual revenue is currently $78.8M per year.(i)
  • Essilor Prescription Safety Eyewear's estimated revenue per employee is $251,000

Employee Data

  • Essilor Prescription Safety Eyewear has 314 Employees.(i)
  • Essilor Prescription Safety Eyewear grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$30.6M1224%N/AN/A
#2
$18.6M7435%N/AN/A
#3
$75.6M30120%N/AN/A
#4
$12M484%N/AN/A
#5
$2.8M1110%N/AN/A
#6
$3M120%N/AN/A
#7
$24.6M985%N/AN/A
#8
$11.5M4621%N/AN/A
#9
$7.3M294%N/AN/A
#10
$13.8M55-10%N/AN/A
Add Company

What Is Essilor Prescription Safety Eyewear?

Essilor prescription safety eyeglasses are your ultimate solution for employee vision protection. As the leading manufacturer of prescription lenses in the U.S., Essilor is proud to offer our superior lens technology and innovation in prescription safety glasses. Our dedication to exceptional quality and devotion to rigorous research and development is evident in every aspect of our Safety Lens category. Essilor is passionate about performance, and it shows. Our prescription safety glasses feature exclusive lens technology from our family of premium brands, like Varilux®, Crizal® and Transitions® adaptive lenses™. This helps ensure your employees will experience their best possible vision in all situations while on the job. Then, we combine these technologies with the impact and chemical resistance of rugged polycarbonate materials. The result is workplace eyewear that is durable, accurate, comfortable, and meets all the latest ANSI Z87.1-2015 standards.

keywords:N/A

N/A

Total Funding

314

Number of Employees

$78.8M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$99.4M31810%N/A
#2
$117.5M3247%N/A
#3
$136.1M3306%N/A
#4
$87.2M33273%N/A
#5
$141.9M3447%N/A